Arachidonic acid prevents fatty liver induced by conjugated linoleic acid in mice.
Conjugated linoleic acid (CLA) has anti-obesity effects, but induces fatty liver in mice. The present study investigated whether co-administration of arachidonic acid (ARA) attenuates fat accumulation in the mouse liver induced by CLA. Male mice (8 weeks old) were given diets with either no addition of dietary fat (control), 3 % linoleic acid (LA), 3 % CLA, 3 % CLA+1 % ARA, or 3 % CLA+2 % ARA for 4 weeks. The perirenal fat weight in ARA-treated groups decreased similarly as with CLA alone, when compared to control or LA. Plasma TAG concentration was significantly higher in the CLA group than in either CLA+ARA group, while plasma cholesterol and NEFA concentrations did not vary among the groups. In contrast to visceral fat, liver weight was significantly higher in the CLA group than in the control or LA groups, and the effects of CLA were attenuated by ARA. TAG and cholesterol were markedly accumulated in the liver with dietary CLA, whereas co-administration with ARA, at either concentration, suppressed CLA-induced lipid accumulation. Liver PGE(2) was enhanced by a combination of CLA and ARA when compared with CLA alone, but PGE(1) level was not significantly different among groups. In conclusion, fatty liver induced by CLA was attenuated by co-administration with ARA, furthermore, a combination of these fatty acids maintained the anti-obese effect of CLA.
Oikawa
Daichi
D
Laboratory of Advanced Animal and Marine Bioresources, Graduate School of Bioresources and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan. daichioikawa@kyudai.jp
Tsuyama
Shoichiro
S
Akimoto
Yoriko
Y
Mizobe
Yurika
Y
Furuse
Mitsuhiro
M
D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D015232:Dinoprostone / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005234:Fatty Liver / Q000139:chemically induced* / Q000378:metabolism / Q000517:prevention & control*; D044243:Linoleic Acids, Conjugated / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D051379:Mice; D014280:Triglycerides / Q000097:blood
D005230:Fatty Acids, Nonesterified; D044243:Linoleic Acids, Conjugated; D014280:Triglycerides; D016718:Arachidonic Acid; D002784:Cholesterol; D015232:Dinoprostone